Program
IRL757
A development code.
Its studies are mostly in Parkinson Disease, led by Integrative Research Laboratories AB.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Integrative Research Laboratories AB | 31 open or running | phase 2since Feb 17, 2026 | May 29, 2024 | May 2027phase 2 · NCT07461220 |
Also a collaborator on its studies: Otsuka.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 29, 2024First study: phase 1 study in Not DeterminedFirst studyNCT06493045 · 82 enrolled · Sweden
- Oct 22, 2024Phase 1 study in LethargyNCT06699628 · 12 enrolled · Sweden
- Feb 17, 2026Phase 2 study in Parkinson DiseasePhase 2 reachedNCT07461220 · 75 planned · Bulgaria, Germany, Poland and more
Ahead
- May 2027Primary completion: phase 2 study in Parkinson DiseaseNCT07461220
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07461220Parkinson Disease · Bulgaria, Germany, Poland and more | 2 | Recruiting | May 2027 | 75 |
| NCT06699628Lethargy · Sweden | 1 | Completed | Nov 11, 2024 | 12 |
| NCT06493045Not Determined · Sweden | 1 | Completed | Feb 7, 2025 | 82 |
How it is read
Names in the registry
- “IRL757”, 3 entries
Codes read as this program: IRL757.
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.